Gan to kagaku ryoho. Cancer & chemotherapy
-
Gan To Kagaku Ryoho · May 2006
Comparative Study[Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].
We performed a retrospective study that compared the efficacy and safety of ramosetron with azasetron in a case of acute and delayed emesis induced by cisplatin (CDDP)-included chemotherapy in patients with lung cancer. The study subjects were 100 lung cancer patients treated with combination therapy of cisplatin, ifosfamide, irinotecan (CIC therapy). The ramosetron group and azasetron group received, respectively, ramosetron 0.3 mg or azasetron 10 mg intravenous injection, 30 minutes prior to CDDP. ⋯ Adverse effects were observed in 27 cases in the ramosetron group and 24 cases in the azasetron group. However, because the symptoms were all mild, we did not consider there was any safety problem. In conclusion, it was suggested that ramosetron is a clinically useful treatment for acute and delayed emesis induced by cisplatin-induced chemotherapy in patients with lung cancer.
-
Gan To Kagaku Ryoho · Apr 2006
Case Reports[Efficacy of controlled-release oxycodone for dyspnea in cancer patients--three case series].
Dyspnea is a common symptom in patients with advanced cancer. Systemic morphine administration has been reported as an effective pharmacological treatment to control dyspnea. ⋯ In all cases, both opioids provided equivalent effects for the palliation of cancer dyspnea with no significant adverse effects. Future studies in the appropriate clinical designs will be needed to confirm our findings.
-
Gan To Kagaku Ryoho · Mar 2006
Review[Efficacy of postoperative adjuvant therapy for resected non-small cell lung cancer--an evidence-based review].
Efficacy of postoperative adjuvant therapy for non-small cell lung cancer (NSCLC) was examined based on recent evidence. In 2003, when a clinical guideline for lung cancer had been published, the efficacy of postoperative adjuvant therapy had not been established. However, results of randomized controlled studies and metaanalysis on the efficacy of postoperative chemotherapy, platinum-based chemotherapy or UFT, were presented at the annual meetings of the American Society of Clinical Oncology (ASCO) held in 2003-2005. Thus, postoperative adjuvant chemotherapy for completely resected NSCLC cases is now a standard care of therapy.
-
Gan To Kagaku Ryoho · Mar 2006
Case Reports[A case of long-term, high-dose transdermal fentanyl application for lung cancer pain].
Transdermal fentanyl patch represents a new administration route for cancer pain relief. We reported here a successful experience with a high-dose of transdermal fentanyl for cancer pain therapy. ⋯ During the past 15 months, she has been treated with 30 mg or more of transdermal fentanyl for cancer pain relief. No severe side effects were observed, and she experienced a better quality of life at home using this patch long-term.
-
Gan To Kagaku Ryoho · Feb 2006
Case Reports[Three cases of drug-induced akathisia due to antiemetics during cancer palliative care].
Three cases of drug-induced akathisia during palliative care in terminal cancer patients were reported. Antiemetics (metoclopramide and prochlorperazine) possessing a central antidopaminergic effect were suspected to have caused the akathisia. Akathisia, as well as extrapyramidal symptoms, is a common and unpleasant complex neurobehavioral adverse effect of conventional antipsychotic drugs. ⋯ Drugs which have been found to have some efficacy in the treatment of akathisia are anticholinergics, beta-blockers, benzodiazepines and clonidine. Though a number of other treatments have been proposed, no trial-based evidences for treatment of akathisia have been available. It is important that akathisia is recognized and treated appropriately as an adverse reaction to drugs and a further increase in antipsychotic medication dosage may further exacerbate the condition.